METHODS FOR DESIGNING INHIBITORS OF SERINE/THREONINE KINASES AND TYROSINE KINASES

Abstract: The invention relates to methods for designing inhibitors of serine/threonine kinases and tyrosine kinases, particularly MAP kinases, through the use of ATP-binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound.

Description: METHODS FOR DESIGNING INHIBITORS OF SERINE/THREONINE KINASES AND TYROSINE KINASES TECHNICAL FIELD OF INVENTION The invention relates to methods for designing inhibitors of serine/threonine kinases, particularly MAP kinases, and tyrosine kinases through the use of ATP- binding site mutants of those kinases. The methods of this invention take advantage of the fact that the mutant kinases are capable of binding inhibitory compounds -of other kinases with greater affinity than the corresponding wild-type kinase. The invention further relates to the mutant kinases themselves and crystallizable co-complexes of the mutant kinase and the inhibitory compound. BACKGROUND OF THE INVENTION Kinases and protein kinase cascades are involved in most cell signaling pathways, and many of these pathways play a role in human disease. For instance, kinases have been implicated in cell entry into apoptosis [P. Anderson, Microbiol. Mol . Biol . Rev., 61, pp. 33-46 (1997)], cancer [P. Dirks, Neurosurgery, 40, pp. 1000-13, (1997)], Alzheimer's disease [K. Imahori et al., J. Bioche ., 121, pp. 179-88 (1997)] angiotensin II and hematopoietic cytokine receptor signal transduction [B. Berk et al . , Circ. Res., 80:5, pp. 607-16 (1997); R. Mufson, FASEB J . , 11:1 pp. 37-44 (1997)], oncoprotein signaling and mitosis [A. Laird et al . , Cell Signal, 9:3- 4 pp. 249-55 (1997)], inflammation and infection [J. Han et al., Nature, 386 296-9 (1997).] An understanding of -2 - the structure, function, and inhibition of kinase activity could lead to useful human therapeutics. The structures of a number of protein kinases have been solved by X-ray diffraction and analyzed [reviewed m L. Johnson et al . , Cell, 85, pp. 149-158 (1996); E. Goldsmith et al . , Cur. Opin. Struct. Biol., 4, pp. 833-840 (1994); S. Taylor et al . , Structure, 2, pp. 345-355 (1994)]. Enzymes m the kinase family are often characterized by two domains separated by a deep channel. The N-termmal domain creates a binding pocket for the adenine ring of ATP, and the C-termmal domain contains the presumed catalytic base, magnesium binding sites, and phosphorylation lip. Sequence homology among the kinases varies, but is usually highest m the ATP- binding site. ATP is a substrate common for all kinases. Among medically important tyrosme kinases are epiαermal growth factor receptor (EGFR) , platelet-derived growth factor receptor (PDGFR) , fibroblast growth factor receptor (FGFR), Flk-1, and src. One particularly important class of serine/threonme kinases are the mammalian mitogen- activated protein (MAP) 1 kinases. These kinases mediate mtracellular signal transduction pathways [M. H. Cobb et al., J. Biol. Chem., 270, pp. 14843-6 (1995); R. J. Davis, Mol . Reprod. Dev., 42, pp. 459-67 (1995)]. Members of the MAP kinase family share sequence similarity and conserved structural domains, and include the extracellular-signal regulated kinases (ERKs) , Jun N- termmal kinases (JNKs) and p38 kinases. JNK and p38 kinases are activated m response to the pro-inflammatory cytokmes TNF-α and mterleukm-l, and by cellular stress such as heat shock, hyperosmolanty, ultraviolet - 3- radiation, lipopolysacchaπdes and inhibitors of protein synthesis [B. Denjard et al . , Cell, 76, pp. 1025-37 (1994); J. Han et al . , Science, 265, pp. 808-11 (1994); J. Ramgeaud et al . , J. Biol. Che ., 270, pp. 7420-6 (1995); L. Shapiro et al . , Proc. Natl. Acad. Sci . U.S.A., 92, pp. 12230-4 (1995)]. In contrast, ERK kinases are activated by mitogens and growth factors [D. Bokemeyer et al., Kidney Int., 49, pp. 1187-98 (1996)]. ERK2 is found m many different cell types. ERK2 is a protein kinase that achieves maximum activity when both Thrl83 and Tyrl85 are phosphorylated by the upstream MAP kinase kinase, MEK1 [N. G. Anderson et al . , Nature, 343, pp. 651-3 (1990); C. M. Crews et al . , Science, 258, pp. 478-80 (1992)]. Upon activation, ERK2 phosphorylates many regulatory proteins, including the protein kinases Rsk90 [C. Bjorbaek et al . , J. Biol . Chem. 270, pp. 18848-52 (1995)] and MAPKAP2 [J. Rouse et al . , Cell, 78, pp. 1027-37 (1994)], and transcription factors such as ATF2 [J. Ramgeaud et al., Mol . Cell. Biol., 16, pp. 1247-55 (1996)], Elk-1 [J. Ramgeaud et al . (1996)], c-Fos [R. H. Chen et al . , Proc. Natl. Acad. Sci. U.S.A., 90, pp. 10952-6 (1993)], and c-Myc [B. L. Oliver et al . , Proc. Soc. Exp. Biol. Med., 210, pp. 162-70 (1995)]. ERK2 is also a downstream target of the Ras/Raf dependent pathways [S. A. Moodie et al . , Science, 260, pp. 1658-61 (1993)] and may help relay the signals from these potentially oncogenic proteins. ERK2 has been shown to p±a^ a role the negative growth control of breast cancer cells [R. S. Frey et al . , Cancer Res . , 57, pp. 628-33 (1997) η and hyperexpression of ERK2 m human breast cancer has been reported [V. S. Sivaraman et al . , J. Clin. Invest., 99, pp. 1478-83 (1997)]. Activated -4- ERK2 has also been implicated the proliferation of endothelin-stimulated airway smooth muscle cells, suggesting a role for this kinase m asthma [A. helchel et al., Am. J. Respir. Cell. Moi . Biol., 16, pp. 589-96 (1997)]. In addition, ERK2 appears to be involved m platelet-derived growth factor-directed migration of vascular smooth muscle cells, suggesting that this kinase may be also be involved m restenosis and hypertension. [K. Graf et al . , Hypertension, 29:1, pp. 334-339 (1997)]. The crystal structures of unphosphorylated p38 [K. P. Wilson et al . , J. Biol. Chem., 271, pp. 27696-700 (1996); Z. Wang et al . , Proc. Natl. Acad. Sci. U.S.A., 94, pp. 2327-32 ( 1997 ); (Brookhaven PDB entry, IWFC)], and ERK2 [F. Zhang et al . , Nature, 367, pp. 704-11 (1994); (Brookhaven PDB entry, 1ERK) ] have been solved. Recently, a phosphorylated ERK2 crystal structure has also been solved [B. J. Canagarajah et al . , Cell, 90, pp. 859-69 (1997)]. The fold and topology of ERK2 is similar to p38 [K. P. Wilson et al . (1996)], and the two proteins are 48 identical m ammo acid sequence. p38 was identified as a kinase that was phosphorylated on tyrosme following stimulation of monocytes by LPS [J. C. Lee et al . , Nature, 372, pp. 739- 46 (1994)]. p38 kinase was cloned [J. Han et al . (1994)] and shown to be the target for pyridmylimidazole compounds that block the production of IL-lβ and TNF-α by monocytes stimulated with LPS [J. C. Lee et al . (1994)]. SB203580, a 2 , 4 , 5-trιarylιmιdazole, is a potent p38 kinase inhibitor that is selective relative to other kinases, including other closely related MAP kinases [A. Cuenda et al . , FEBS Lett., 364, pp. 229-33 (1995); A. Cuenda et al . , EMBO J . , 16, pp. 295-305 (1997)]. The - 5- structure of SB203580 m complex with p38 has been reported [L. Tong et al . , Nat. Struct. Biol., 4, pp. 311- 6 (1997)]. The crystal structure of a different pyridmylimidazole compound, VK-19,911, 4-(4- fluorophenyl) -1- (4-pιperιdmyl ) -5- (4-pyrιdyl) -lmidazole m complex with p38 has also been described [K. P. Wilson et al., Chem. & Biol. , 4, pp. 223-231 (1997)]. These structures identified the residues important for binding pyridinyl-imidazoles, and revealed that both compounds bind within the ATP binding site of p38. Many of these residues are conserved m ERK2, but there are enough differences that omding of pyridmyl-imidazole compounds does not occur. A similar situation exists for JNK3, which also shares structural similarity to p38, but is unable to bind pyridmyl-imidazole inhibitors. This same type of scenario, wherein a compound binds to one family member, but not to the majority of others, is also likely to occur m other serme/threonme kinase and tyrosme kinase families. However, the kinase family members that do not share affinity for a compound that binds to one member may be equally, if not more important from a medical standpoint. Thus, there is an ongoing need to identify potential inhibitors of those other kinases. SUMMARY OF THE INVENTION The present invention solves the problem indicated above by providing a method of identifying potential inhibitors of serme/threonme kinases and tyrosme kinases that are related to a kinase which has a known inhibitor. In particular, the invention provides a - 6- method of identifying potential inhibitors of ERK2 and JNK3, as well as other MAP kinases that are unable to bind pyridmylimidazole compounds which inhibit the MAP kinase p38. The method of the present invention is based upon the identification of residues m the ATP-bmdmg pocket of a first kinase that make close contacts with an inhibitor. This may be achieved by crystallizing a first kinase with a known inhibitor and analyzing the data. Alternatively, such data may already be available. Once this information is provided, related kinases are identified using readily available protein alignment software and databases of proteins. Related kinases which share some, but not all, of the first kinase ATP binding pocket ammo acid residues that interact with the known inhibitor are selected as candidates for which new inhibitors may be designed. One or more of the ammo acid residues in the ATP binding pocket of the related ("second") kinase which could potentially interact with the known inhibitor, but which are different from the corresponding ammo acid residue m the first kinase are then altered to increase affinity for the known inhibitor. This "mutated" or "mutant" second kinase is also part of the present invention. The ability of the known inhibitor to bind to the mutant second kinase with good affinity is confirmed by Dindmg studies. Once affinity is confirmed, the mutant second kmase-known inhibitor complex is subjected to molecular modeling means (X-ray crystallography, 3-D computer analysis) to determine how to alter the known inhibitor to create a compound which inhibits the wild type second - 7 - kmase . The crystallizable co-complex of the mutant second kinase with the known inhibitor is also a part of th s invention. DETAILED DESCRIPTION OF THE INVENTION According to one embodiment, the invention provides a method for designing an inhibitor of a second serme/threonme kinase or a second tyrosme kinase. This method comprises the steps of: a. identifying ammo acids m an ATP binding site of a first serme/threonme kinase or a first tyrosme kinase which form close contacts with a compound bound to said ATP binding site; b. employing protein alignment means to identify a second serme/threonme kinase or a second tyrosme kinase that form some, but not all, of the close contacts formed between said compound and said first serme/threonme kmase or said first tyrosme kinase; c. altering an ammo acid m the ATP binding site of said second serme/threonme kinase or said second tyrosme kinase to create a mutant second serme/threonme kinase or a mutant second tyrosme kmase, wherein said compound binds with at least 10-fold greater affinity to said mutant second kinase than to saiα second kinase; d. confirming that said compound binds it- greater affinity to said mutant second serme/threonme kinase or said mutant second tyrosme kmase than to said second serme/threonme kinase or sa-α second tyrosme kinase; and -8- e. using molecular modeling means to modify said compound to create an inhibitor of said second kinase, such that said inhibitor binds to said second kinase with at least 10-fold greater affinity than said compound binds to said second kinase. The identification of the ammo acids m an ATP binding site of a first serme/threonme kinase or a first tyrosme kinase which form close contacts with a compound bound to said ATP binding site is routinely performed by analyzing the X-ray crystal structure of the first kinase co-complexed with an inhibitor that is known to bind to its ATP binding site, or co-complexed witn ATP itself . Standard X-ray crystallographic techniques, equipment ano software are used to generate crystals of the co-complex, carry out the X-ray diffraction, collect and analyze the data. These techniques, equipment and software are well known m the art. It should be understood, however, that generating the X-ray data is not a required step m the method of this invention. One may begin by having this data (either raw or fully analyzed) hand from previous experiments or from an outside source. One may also begin by acquiring the knowledge of which ammo acids make close contact with the bound inhibitor or ATP directly from another source. The term "close contact", as used herein, means that an atom or atoms of the ATP binding site of the kinase are physically close enough to an atom or atoms of the compound bound to that site and that the atoms are of such a nature as to enable the formation of non- covalent bonds, such as hydrogen bonds or van der Waals - 9- or electrostatic interactions. Physical distances of less than 4A are required to form significant non- covalent interactions. A close contact also includes any covalent interactions between the kinase and the ligand. The choice of inhibitor to bind to the kinase m order to generate information on close contacts depends upon the nature of the kinase. The inhibitor should bind tightly to the kinase and significantly inhibit the ability of the kinase to hydrolyze ATP. Any known inhibitor that has a K d and/or a K of less than 1 uK w ll suffice. Preferably, the inhibitor will have a K„ and/or a K of less than 100 nM. The measurements of K for enzyme inhibition and K_ for binding of a ligand to a protein of interest are well known m the art. These are described, for example, m "Enzyme Structure and Mechanism, Second Edition, " Alan Fersht, ed., W. H. Freeman and Company, New York (1985), tne disclosure of which is herein incorporated by reference . According to a preferred embodiment, the first kinase is a MAP kinase. Even more preferred is that the first Kinase be p38 having the ammo acid sequence set forth m SEQ ID NO:l. Preferably, the inhibitor bound to p38 of SEQ ID NO:l is a pyridmyl-imidazole compound. More preferably, the pyridmyl-imidazole compound is selected from SB203580 or SB 202190, which have the structures depicted below: - 10- SOCH3 SB 202190 SB 203580 Other pyridmyl-imidazole compounds that may be useful to co-complex with p38 are described United States patents 5,670,527 and 5,658,903, the disclosures of whicn are herein incorporated by reference. Once the close contact ammo acids have been identified, the next step is to identify a second serme/threonme kinase or tyrosme kinase that forms some, but not all, of the close contacts formed between the ligand and the first kinase. This is achieved by employing protein alignment means comparing the ammo acid sequence of the first kinase with a database containing other kinase ammo acid sequences, such as GenBank. Protein alignment means involve the use of computer software that performs a best fit alignment of a first protein with another, related protein. Several state-of-art computer programs are available for homology comparison and alignment of structure- and sequence- related proteins. One example of homology alignment program is PILEUP (Genetics Computer Group) which compares multiple sequences of related proteins and nucleotides and -11- generates an alignment of these sequences for comparison. PILEUP allows one to use primary protein sequence similarity and structure similarity as parameters to set up an alignment of multiple proteins. Once the close contact ammo acid residues of first kmase are defined, corresponding residues m the second kinase of interest can be identified from the alignment generated by the program. From a practical consideration, the ammo acid residues of the second kmase that align with the close contact ammo acids of the first kmase should differ at a least 1 and not more than 4 residues. Protein alignment means will identify related kinases and the ammo acid residues thereof that align with the close contact ammo acids of the first kinase and thus could potentially form close contacts with the inhibitor of the first kinase. The ammo acids of this second kmase that align with the close contact ammo acids of the first kinase, but differ m identity and/or nature therefrom, are the ammo acids that will be targeted for replacement the next step of the method. The term "nature" of an ammo acid, as used herein, means its physicochemical characteristics, e.g., polar, non- polar, hydrophobic, hydrophilic, bulky side group, non- bulky side group, acidic, basic, etc. According to one preferred embodiment, the second kinase is a MAP kinase. Even more preferred is that the second kinase be ERK-2 having the ammo acid seσuence set forth m SEQ ID NO: 2, wherein ammo acid 103 is lsoleuc e, ammo acid 105 is glutamme, ammo acid 106 is aspartic acid, ammo acid 109 is glutamic acid and ammo acid 110 is threonme; or JNK3 comprising at least -12- ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is methionme and ammo acid 150 is aspartic acid. Those particular ammo acids will be changed to be identical to, or at least similar m nature to, the corresponding ammo acid m the first kinase to create a mutant second kmase. This alteration will increase the ability of the ligand to bind to the second (now mutant) kinase by at least 10-fold over its affinity for the un utated second kinase, as measured by K x or K . If the ligand has no detectable binding to the unmutated second kinase (and therefore a 10-fold increase may not be measurable) , the ligand should bind to the mutated second kinase with a K and/or K d of less than 10 uM. The alteration of one or more ammo acid m the ATP binding site of the second kinase according to the next step m the method may be achieved by standard molecular biological means. For example, site-directed mutagenesis, PCR, or other methods of altering the DNA or a cDNA encoding the second kinase is utilized to change an ammo acid m that kinase to create a mutant second Kinase. Obviously, the mutant kinase will be produced by recombmant DNA means, which are well known m the art. In one preferred embodiment, the mutant second kinase is an ERK-2 mutant having the ammo acid sequence set forth m SEQ ID NO: 2, wherein ammo acid 105 is threonme or alanme. According to another preferred embodiment, the mutant second kinase is an ERK-2 mutant having the ammo acid sequence set forth m SEQ ID NO: 2, wherein ammo acid 105 is threonme or alanme, ammo aciα 103 is leucme, ammo acid 106 is histidme, ammo acid 109 is glycme and ammo acid 110 is alanme. In this embodiment, although 5 ammo acids have been changed -13- as compared to naturally occurring ERK-2, only ammo acid 105 is considered to be a close contact ammo acid. The other altered ammo acids were chosen based on proximity to ammo acid 105 and because they differed from those present m p38. In another preferred embodiment, the mutant second kinase is JNK3 mutant kmase comprising ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is alanme. According to another preferred embodiment, the mutant second kinase is JNK3 mutant kinase comprising ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is aianine ano ammo acid 150 is glycme. Once the mutant second kmase has been created at the DNA level and expressed m an appropriate host cell ana isolated, the next step of the method of this invention is to confirm its ability to bind to the ligand of the first kinase. This may be achieved by various metnods well known m the art for determining K 2 and/or K . The step following confirmation of binding between the ligand and the mutant second kinase is the moαification of the ligand so that is capable of binding to and inhibiting the ATP binding site of the native form of the second kinase. This step is achieved using molecular modeling means that typically involve solving the crystal structure of the mutant second kmase/ligand co-complex; analyzing the contacts made between the co- comp ex components; comparing how the ligand would interact with the native second kinase using computer simulation and the appropriate software; and altering tnose portions of the ligand that are steπcally hindered from or otherwise incompatible with binding to the native -14- second kinase. The software typically utilized m molecular modeling is capable of achieving each of these steps, as well as suggesting potential replacements for various moieties of the ligand that would increase association with the native second kinase. One skilled m the art may use one of several methods to screen chemical moieties to replace portions of the ligand so that binding to the native second kinase is optimized. This process may begin by side-by-side visual inspection of, for example, native second kinase ana tne mutant second kinase ATP binding sites on the computer screen based on the X-ray structure of the liαand/mutant second kinase co-complex. Modified ligands may then be tested for their ability to dock to the native second kinase using software such as DOCK and AUTODOCK followed by energy minimization and molecular dynamics with standard molecular mechanics force fields, such as CHARMM and AMBER. Specialized computer programs may also assist m the process of replacement fragments: 1. GRID (P. J. Goodford, "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules", J. Med. Chem. , 28, pp. 849-857 (1985)). GRID is available from Oxford University, Oxford, UK. 2. MCSS (A. Miranker et al . , "Functionality Maps of Bmαing Sites: A Multiple Copy Simultaneous Search Metnoα." Proteins: Structure, Function and Genetics, 11, pp. 29-34 (1991)). MCSS is available from Molecular Simulations, Burlington, MA. - 15- 3. AUTODOCK (D. S. Goodsell et al . , "Automated Docking of Substrates to Proteins by Simulated Annealing", Proteins: Structure, Function, and Genetics, 8, pp. 195- 202 (1990)). AUTODOCK is available from Scripps Research Institute, La Jolla, CA. 4. DOCK (I. D. Kuntz et al . , "A Geometric Approach to Macromolecule-Ligand Interactions", J. Mol . Biol . , 161, pp. 269-288 (1982)). DOCK is available from University of California, San Francisco, CA. Alternatively, the portion of the ligand that makes favorable contacts with the identical ammo acids m both the mutant and the native second kmase may be retained as a scaffold and used m software programs that create theoretical inhibitors based upon the structure of the native second kinase ATP binding site. These programs include : 1. LUDI (H.-J. Bohm, "The Computer Program LUDI : A New Method for the De Novo Design of Enzyme Inhibitors", ^ Comp. A d. Molec. Design, 6, pp. 61-78 (1992)). LUDI is available from Biosym Technologies, San Diego, CA. 2. LEGEND (Y. Nishibata et al., Tetrahedron, 47, p. 8985 (1991)). LEGEND is available from Molecular Simulations, Burlington, MA. 3. LeapFrog (available from Tripos Associates, St. Louis, MO) . -16- Other molecular modeling techniques may also be employed m accordance with this invention. See, e.g., N. C. Cohen et al . , "Molecular Modeling Software and Methods for Medicinal Chemistry, J. Med. Chem., 33, pp. 883-894 (1990). See also, M. A. Navia et al., "The Use of Structural Information m Drug Design", Current Opinions m Structural Biology, 2, pp. 202-210 (1992) . Once a compound has been designed or selected by the above methods, the efficiency with which that entity may bind to the native second kinase may be tested and further optimized by computational evaluation. An entity designed or selected as binding to the native second kinase ATP binding pocket may be further computationally optimized so that m its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme. Such non- complementary (e.g., electrostatic) interactions include repulsive charge-charge, dipole-dipole and charge-dipole interactions. Specifically, the sum of all electrostatic interactions between the inhibitor and the kmase when the inhibitor is bound to the ATP binding pocket preferaoly make a neutral or favorable contribution to the enthalpy of binding. Specific computer software is available m the art to evaluate compound deformation energy and electrostatic interaction. Examples of programs designed for such uses include: Gaussian 92, revision C [M. J. Frisch, Gaussian, Inc., Pittsburgh, PA ©1992]; AMBER, version 4.0 [P.A. Kollman, University of California at San Francisco, 01994]; QUANTA/CHARMM [Molecular Simulations, Inc., Burlington, MA ©1994]; and Insight II/Discover (Biosysm Technologies Inc., San Diego, CA -17- 01994). These programs may be implemented, for instance, using a Silicon Graphics workstation, Indigo^ or IBM RISC/6000 workstation model 550. Other hardware systems and software packages will be known to those skilled m the art. Once the second kinase ATP bmdmg-pocket inhibitory entity has been optimally selected or designed, as described above, substitutions may then be made m some of its atoms or side groups m order to improve or modify its binding properties. Generally, initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. Such substituted chemical compounds may then be analyzed for efficiency of fit to the second kinase ATP binding pocket by the same computer methods described m detail, above . According to another embodiment, the invention provides a mutant second kinase disclosed above. Such a kinase is enzymatically active m its ability to hyαrolyze ATP and comprises an ammo acid substitution (as compared to the native second kinase) that allows a compound that binds to the ATP binding site of a first serme/threonme kinase or tyrosme kinase to also bind to the ATP binding site of said second serme/threonme or tyrosme kinase. It is preferred that the ATP binding site of the native second kinase, which lacks the ammo ac d substitution present m the mutant, binds said compound with at least 10-fold lower affinity than said mutant kinase. Preferably, the mutant kinase is an ERK-2 kinase having the ammo acid sequence of SEQ ID NO: 2, -18- wherem ammo acid 105 is threonme or alanme; or a mutant JNK3 kinase comprising ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is alanme. According to another preferred embodiment, both the native second kinase and the first kinase are MAP kinases. More preferred is when the first kinase is p38 having the ammo acid sequence of SEQ ID NO:l. Even more preferred is when the native second kinase is ERK-2 having the ammo acid sequence of SEQ ID NO: 2, wherein ammo acid 103 is leucme, ammo acid 106 is histidme, ammo acid 109 is glycme ammo acid 110 is alanme; or JNK3 comprising at least ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is methionme and ammo acid 150 is aspartic acid. The most preferred of these embodiments is wherein the compound that binds to the first kinase and the mutant second kinase is a pyridmyl- imidazole inhibitor of p38, preferably selected from SB203580 or SB202190. After aligning the ammo acid sequences of ERK2 and p38, we determined that there was a difference m ammo acid type between aligned ERK2 ammo acid 105 (glutamme) and p38 ammo acid 106 (threonme) (see SEQ ID NOS: 1 and 2). Thus, we changed the ERK2 glutamme residue to an ammo acid with a smaller side group, preferably threonme or alanme. The resulting mutant ERK2 enzyme retains its enzymatic activity and can bind a pyridmyl-imidazole inhibitor of p38. The corresponding ammo acids that need to be altered m other MAP kinases so that they bind pyπdmyl- lmiαazole compounds with greater affinity can be identified by aligning its ammo acid sequence with that of ERK2 and/cr p38, as discussed above. The ammo acid - 1 9- that aligns with amino acid T106 of p38 (SEQ ID N0:1) and Q105 of ERK2 (SEQ ID NO : 2 ) is the one that will be targeted for substitution. The ERK2 mutant containing the above-indicated ammo acid substitution at amino acid 105 plus the following amino acid substitutions: isoleucine-to-leucine at amino acid 103, aspartic acid-to-histidine at ammo acid 106, glutamic acid-to-glycine at amino acid 109 and threonme-to-alanme at amino acid 110; maintains its enzymatic activity, and binds more tightly to pyridinyl- lmiαazole compounds than the ERK2 with the single substitution at ammo acid 105. In corresponding fashion, we determined that in wild-type JNK3, amino acid 146 (methionine) (SEQ ID NO: 3) aligned with ThrlOβ of p38. Thus, we changed the methionme residue to an alanine. The resulting JNK3 mutant retained its enzymatic activity and bound pyridmyl-imidazole compounds with at least 10-fold greater affinity than wild-type JNK3. In order that the invention described herein may oe more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner. EXAMPLE 1 Cloning, Mutagenesis And Expression of Kinases A. p38 Expression, purification and activation of p38 MAP kmase was as described in K. P. Wilson et al . , Chem. & B ol. , 4, pp. 223-231 (1997), the disclosure of which -20- ιs herein incorporated by reference. B. ERK2 Standard, well-known methods were used for manipulations of recombmant DNA. All subclones were verified by nucleotide sequence analysis of both strands using an Applied Biosystems 373A DNA Autosequencer) . An ERK2 cDNA was cloned by reverse transcription and subsequent polymerase chain reaction (RT-PCR) of total RNA (Qiagen) prepared from human peripheral lymphocytes (PBLs) which were stimulated with 10 ng/ml phorool, 12-myrιstate, 13-acetate (PMA) and 250 ng/ml lonomycm for 72 hours. The forward primer 5'- GAACGGCGGGCAGCCAACATGGCGGCGGCG-3 ' (SEQ ID NO : 4 ) and the reverse primer 5 ' GGGCTCGAGCCTGACAAATTTAAGATCTGTATCCTG-3 ' (SEQ ID NO: 5) were used to generate an ERK2 PCR fragment (RNA PCR kit, Perkm-Elmer) which was cloned into pT7- Blue (Novagen) to yield pT7-ERK2. For bacterial expression of recombmant ERK2, a (His) 6 metal affinity tag and a thrombm cleavage site were introduced at the N-termmus of the translation product. Simultaneously, Ndel and BamEI sites were added at the 5'- and 3' -end, respectively, by PCR using the forward primer 5 ' -TTAACATATGGCGGCGGCGGCGGCGGCG-3 ' (SEQ ID NO: 6) and the reverse primer 5 ' -CCCACAGGATCCGATCTGTATCCTG -3' (Perkm-Elmer) (SEQ ID NO:7) . The Ndel-BamEI double-digested PCR fragment was cloneo into the appropriate sites of pET-15b (Novagen) to yieid pET-ERK2, which was used to transform E. coll BL21(DE3) (Novagen). Freshly transformed bacteria were grown m LB broth supplemented with 100 μg/ml carbenicillm at 30°C to -21- an OD600 of 0.7 - 0.9, induced with 1 mM isopropylthiogalactoside (IPTG) for 2 hours, harvested by low speed centπfugation and stored at -70°C until use. To facilitate construction of several ERK2 mutants, a silent mutation was introduced into the ERK2 cDNA that provided an additional, single H-mdlll restriction site near the region of mutations. This ERK2 variant (ERK2-HIII) and several ERK2 mutants were generated by PCR using PT7-ERK2 as template, a forward primer containing an internal SacII site (underlined) , 5 ' -GATGGTCCGCGGGCAGGTGTTCG-3 ' (SEQ ID NO : 8 ) and the following reverse primers containing a .Hindi11 site (underlined) and one or several mutated nucleotides (bold letters) : 1) for ERK2-HIII 5 ' -GTGTCTTCAAAAGCTTGTAAAGATCTGTTTCC-3 ' (SEQ ID NO: 9) ; 2) for ERK2 (Q103T) 5 ' -CAAAAGCTTGTAAAGATCTGTTTCCATGAGGTCCGTTACTAT-3 ' ; (SEQ ID NO : 10 ) 3) for ERK2 (Q103A) 5 ' -CAAAAGCTTGTAAAGATCTGTTTCCATGAGGTCCGCTACTAT-3 ' (SEQ ID NO : 11 ) ; and 4) for ERK2 ( I101L, Q103T, D104H, E107G, T108A) , 5 ' -CAAAAGCTTGTAAAGATCTGCTCCCATGAGGTGCGTTACTAGATATAC-3 ' (SEQ ID NO:12) . Each of these PCR fragments was digested with SacII and Hmdlll. Using the forward primer 5 ' -GATCTTTACAAGCTTTTGAAGACACAAC-3 ' (SEQ ID N0-13) and reverse primer 5 ' -CTTGGTGTAGCCCTTGGAATTCAACATA-3 ' (SEQ ID NO:I4), a second ERK2 PCR fragment was generated extending from the novel ffmdIII site to an MscI site. Ligation of the SacI l-Hmdl U and Hmdl l l-Mscl PCR -22 - fragments into SacII- scI double-digested pT7-ERK2 yielded pT7 subclones for the ERK2-HIII variant and all ERK2 mutants. These were used to isolate SacII-XhoI ERK2 cDNA fragments which were ligated into the appropriate restriction sites of pET-ERK2 for bacterial expression of (His) 6-tagged recombmant proteins as described above. C. MEKl A cDNA encoding a constitutively active mutant of mouse MEKl (S218D, S222D) [Huang, 1994 #809] with a C- termmal Glu-Tyr-Met-Pro-Met-Glu (SEQ ID NO: 15) tag plasmid pG-MEKlGlu was obtained from Dr. R.L. Erikson (Harvard University, Cambridge, MA) . For bacterial expression of N-termmally (His) 6-tagged (DD)MEKl, two oligodeoxynucleotides 5 ' -CATGGCACACCATCACCATCACCATCCCAAG AAGAAGCCGACGCCCATCCAG-3' (SEQ ID NO: 16) and 5'- CTGGATGGGCGTCGGCTTCTTCTTGGGATGGTGATGGTGATGGTGTGC-3 ' (SEQ ID NO: 17), generating an NcoI-PvuI I fragment, were annealed and inserted together with a Pvul I-BamEI MEKl cDΝA fragment into NcoI-BamEI double-digested pET- BS(+)/T7 to yield pET-BS- (His) 6-MEK1. BL21(DE3) bacteria were transformed for expression of (Hιs)6~ EKl as described above for ERK2. D. JΝK3 To clone JNK3, standard techniques well-known by tnose or ordinary skill in the art were used for manipulations of recombmant DNA. A BLAST search of the EST database using the puolished JNK3αl cDNA [S. Gupta et al . , EMBO J . , 15, pp. 2760-70 (1996)] as a query identified an EST clone (#632588, Research Genetics) that contained the entire -23- codmg sequence for human JNK3αl . Polymerase chain reactions (PCR) using pfu polymerase (Strategene) were used to introduce restriction sites into the cDNA for cloning into the pET-15B expression vector at the col and BamEI sites for expression of the protein m E. coll . Due to the poor solubility of the expressed full length protein (Met 1-Gln 422; SEQ ID NO: 3), an N-termmally truncated protein starting at Ser residue at position 40 (Ser 40), corresponding to Ser 2 of JNK 1 and 2 proteins (SEQ ID NOS: 33 and 32), preceded by Met (initiation) and Gly residues, was produced. The Gly residue was added m order to introduce an Ncol site for cloning into the expression vector. Further, serial C-termmal truncations were performed by PCR. This construct, which was prepared by PCR using deoxyoligonucleotides 5' GCTCTAGAGCTCCATGGGCAGCAAAAGCAAAGTTGACAA 3' (forward primer with initiation codon underlined) (SEQ ID NO: 18) and 5' TAGCGGATCCTCATTCTGAATTCATTACTTCCTTGTA 3' (reverse primer with stop codon underlined) (SEQ ID NO: 19) as primers and confirmed by DNA sequencing, encodes ammo acid residues Ser40-Glu402 of JNK3αl (ammo acid 40-402 of SEQ ID NO: 3), preceded by Met and Gly residues (herein referred to as "tJNK3αl") . Site directed mutagenesis of tJNK3αl m the expression vector pET-15B was carried out using the Stratagene R QuikChange™ site-directed mutagenesis kit. Oligonucleotioes were designed and synthesized to create tne tJNK3αl M146A, tJNK3αl M146T and tJNK3αl D150G. The sequence of oligonucleotide pairs used m the mutagenesis were: 1) JNK3 M1 6A - 5' CCA AGA TGT TTA CTT AGT Age GGA ACT GAT GGA TGC CAA 3' (SEQ ID NO: 20) and its -24 - complement ; 2) JNK3 M1 6T - 5' CAA GAT GTT TAC TTA GTA acG GGA CTG ATG GAT GCC AAC 3' (SEQ ID NO: 21) and its complement; and 3) JNK3 D150G - 5' GTA ATG GAA CTG ATG GgT GCC AAC TTA TGT CAA GTG 3' (SEQ ID NO: 22) and its complement. Mutant bases are present m lower case. For each mutation, the tJNK3αl pET-15B plasmid was denatured and annealed with the appropriate oligonucleotide pair. PCR reactions were performed using Pfu DNA polymerase to yield nicked circular strands which were digested with Dprl to remove the non-mutated parental DNA template. The resulting material was transformed into XLl-Blue. Al-L mutations were verified by nucleotide sequence analysis using an Applied Biosystems 373A DNA Autosequencer . For bacterial expression, E. coll strain BL21 (DE3) (Novagen) was transformed with tJNK3αl, tJNK3αl M146A, tJNK3αl M146T or tJNK3αl D150G. These expression constructs were grown at 30°C m shaker flasks into log phase (OD600 ~ 0.8) m LB supplemented with 100 μg/ml carbenicillm. IPTG was then added to a final concentration of 0.8 mM and the cells were harvested 2 hours later by centπfugation. EXAMPLE 2 Purification of MEKl (DD) , ERK2, ERK2 Mutants, JNK3 and JNK3 Mutants A. ERK2, ERK2 mutants and MEKl (DD) Unless otherwise stated all steps were performed at 4°C. E . coll cell paste, with expressed kinase, was resuspended m 10 volumes/g lysis buffer (50 -25- M HEPES, pH 7.8, containing 10° o glycerol (v/v), 250 mM NaCl, 5 mM β-ME, 5 mM lmidazole, 0.1 mM PMSF, 2 μg/ml pepstatm, 1 μg/ml each of E-64 and leupeptin) . Cells were mechanically disrupted using a French press and centrifugation at 35,000 x g for 60 mm. The supernatant was incubated overnight with 1 ml Talon metal affinity resin (Clontech) /5 - 10 mg estimated protein. Resin with bound kinase was poured into a 1.5 x 10 cm column and washed with 20 column volumes of lysis buffer without protease inhibitors, followed by 20 column volumes of wash buffer (50 mM HEPES, pH 7.5, containing 10° glycerol (v/v), 100 mM NaCl, 5 mM β-ME and 10 mM lmidazole) . Protein was eluted m 2-3 column volumes with wash buffer adjusted to pH 8.0 and 100 mM lmidazole. 10c precast SDS-PAGE gels (Novex) were used to identify fractions containing MEKl (DD) , which were concentrated by ultraflltration (Centrιprep-30, Amicon) to 2 ml. Concentrated MEKl (DD) was loaded onto a Superdex-75 (60 x 1.6 cm, Pharmacia) column equilibrated with 20 mM HEPES, pH N 5 , containing 10% glycerol (v/v), 100 mM NaCl and 2 mM DTT at a flow rate of 1 ml/mm. Eluted MEKl (DD) fractions were stored at -70°C. All ERK2 kinases were affinity purified as described for MEKl (DD) , then diluted to < 25 mM NaCl with 20 mM HEPES, pH 8.0, containing 10% glycerol (v/v) and 2 mM DTT (buffer A), 0.45 μm filtered, and loaded onto a MonoQ (HR 5/5) anion-exchange column equilibrated m buffer A. After washing with 5% buffer B (buffer A + 1M Nad,, the ERK2 proteins were eluted m a 5-20% buffer B gradient developed over 60 mm at 0.5 ml/mm and fractions containing ERK2 were stored at -70°C. Protein concentrations were determined from the A280 using -26- caIculated extinction coefficients of 23,600 and 42,000 M _1 cm -1 for MEKl (DD) and ERK2, respectively. B. JNK3 and JNK3 Mutants E. coli cell paste containing JNK3 was resuspended m 10 volumes/g lysis buffer (50 mM HEPES, pH 7.2, containing 10% glycerol (v/v), 100 mM NaCl, 2 mM DTT, 0.1 mM PMSF, 2 μg/ml Pepstatm, Iμg/ml each of E-64 ano Leupeptm) . Cells were lysed on ice using a microfluidizer and centrifuged at 100, 000 x g for 30 mm at 4°C. The 100,000 x g supernatant was diluted 1:5 with Buffer A (20 mM HEPES, pH 7.0, 10% glycerol (v/v), 2 mM DTT and purified by SP-Sepharose (Pharmacia) cation- exchange chromatography (column dimensions: 2.6 x 20 cm) at <°C. The resm was washed with 5 column volumes of Buffer A, followed by 5 column volumes of Buffer A containing 50 mM NaCl. Bound JNK3 was eluted with a 7.5 column volume linear gradient of 50-300 mM NaCl, where JNK3 eluted between 150-200 mM NaCl. EXAMPLE 3 In Vitro Phosphorylation of ERK2 and JNK3 proteins ERK2 was diluted to 0.5 mg/ml in 50 mM HEPES, pH 8.0, 10% glycerol, 100 mM NaCl, 2 mM DTT, 20 mM β- glycerophosphate, 10 mM MgCl 2 . Activation was initiated by addition of 2.5 mM ATP and a 1/25 molar ratio of MEKl(DD) for 1 h at 25°C. Activated ERK2 proteins were diluted to 25 mM NaCl and purified by anion-exchange as described. The ERK2 mutants are phosphorylated m vitro as efficiently as wild-type enzyme by MEKl. Five mg of JNK3 was diluted to 0.5 mg/ml m 50 -27 - mM HEPES buffer, pH 7.5, containing 100 mM NaCl, 5 mM DTT, 20 mM MgCl , 1 mM ATP. GST-MKK4 (DD) kinase (the upstream mutant form of one of the activating kinases of JNK3) was added at a molar ratio of 1 GST-MKK4 : 2.5 JNK3. After 30 mm at 25°C the reaction mixture was concentrated 5-fold by ultrafiltration m a Centrιprep-30 (Amicon, Beverly, MA) , then diluted back up to 10 ml and an additional 1 mM ATP added. This procedure was repeated three times to remove ADP and replenish ATP. The final (third) addition of ATP was 5 mM and the mixture incubated overnight at 4°C. The activated JNK3/GΞT-MKK (DD) reaction mixture was exchanged into 50 mM HEPES buffer, pH 7.5, containing 5 mM DTT and 5% glycerol (w/v) by dialysis or ultrafiltration . The reaction mixture was adjusted to 1.1 M potassium phosphate, pH 7.5, and purified by hydrophobic interactions chromatography (at 25°C) using a Rainm Hydropore column. GST-MKK4 and unactivated JNK3 do not bind under these conditions and when a 1.1 to 0.05M potassium phosphate gradient is developed over 60 mm at a flow rate of 1 ml/mm, doubly phosphorylated JNK3 is separated from singly phosphorylated JNK. Activated JNK3 (i.e. doubly phosphorylated) was stored at -70°C at 0.25-1 mg/ml. EXAMPLE 4 Kinase Assays A coupled spectrophotometπc assay was used m which ADP generated by ERK2, JNK3 or p38 kinase was converted to ATP by PK with the concomitant production of pyruvate from PEP. LDH reduces pyruvate to lactate with the oxidation of NADH. NADH production was monitored at -28- 340 nm using a microplate reader for 20 mm at 30°C. Reactions were m 100 mM HEPES, pH 7.6, 10 mM MgCN , and started by addition of 100 μM ATP. PK (100 μg/ml), LDH (50 μg/ml), PEP (2 mM) and NADH (140 μM) were added in large excess. Addition of 200 μM KRELVEPLTPSGEAPNQALLR (SEQ ID NO: 23) substrate, corresponding to an EGF receptor peptide [F. A. Gonzalez et al . , J. Biol . Chem. , 266, pp. 22159-63 (1991)], allowed measurement of kinase activity. In K determinations, E + I was pre-mcubated for 15 mm at 30°C prior to assay by addition of ATP. Inhibition constants were determined by fitting kinetic data to the Morrison tight-bmdmg equation [J. F. Morrison et al . , Adv. Enzymol. Relat. Areas Mol . Biol., 61, pp. 201-301 (1988)] using KineTic (BioKm, 1992). J2 P incorporation into ATF2 (0.1 mg/ml) by 7.5 nM kinase was assayed for 10 mm at 30°C in 50 mM HEPES, pH 7, 10 mM MgCl and 2 mM DTT, and visualized by autoradiography . The kinase activity of the ERK2 mutants are comparable to wild-type enzyme. However, ERK2 (Q105T) shows a 640 to 2, 500-fold increased binding affinity for the pyridmyl-imidazoles tested (Table I) , using a lower limit of 20 μM for wild-type ERK2 inhibition. ERK2 (Q105A) is even more sensitive to this compound class, exhibiting 1,800 to 25, 000-fold increased binding (Table I) . Mutation of residues, I103L, D106H, E109G, TilOA, m addition to Q105T produced an enzyme (herein referred to as "ERK2(5X)") most sensitive to the pyridmyl-imidazoles, ranging from 0.76 nM for SB203580 to 0. nM for SB202190. The K. values correspond to a 2,900 to 50, 000-fold increase m potency of binding of these compounds. These results indicate that the larger -29- glutamme side chain at residue 105 accounts for the resistance of ERK2 to pyridmyl-imidazoles. TABLE 1. K M for ATP-bmdmg and K x for pyridmyl- lmidazole inhibition of ERK2, ERK2 mutants and p38 kinase . ENZYME K M FOR INHIBITION CONSTANTS, K τ ATP (μM) (NM) SB203580 SB202190 ERK2 (wild-type) 76 ± 14 nil nil ERK2 (Q105A) 51 ± 6 1.2 ± 0.3 0.81 ± 0.19 ERK2 (Q105T) 33 ± 4 13.0 ± 3.6 6.8 ± 0.6 ERK2 (5X) 26 ± 2 0.76 ± 0.14 0.4 ± 0.04 p38 260 ± 30 100 ± 30 30 + 8 1 nιl indicates no inhibition at 20 μM Due to the different K m values for the wild- type and mutant JNK3 enzymes we assayed each one with different ATP concentrations: JNK3 (wild-type) ATP = 30 μM JNK3(M105A) ATP = 150 μM JNK3 (M105A/D109G) ATP = 600 μM Enzyme concentrations m the assay were 5-10 nM. As for ERK2, the kmase phosphate acceptor substrate was the EGF receptor peptide (SEQ ID NO: 23) used at 200 μM. Data analysis to determine K values was also as described for ERK2. Wild-type JNK3 differs from ERK2 in that it is moderately sensitive to SB202190. As seen for ERK2 , removal of the side-chain of Metl46 m JNK3 (the -30- equivalent to Q105 m ERK2 ) causes a dramatic increase m sensitivity towards SB202190 (~4, 000-fold for the M146A mutant) . The double mutant is considerably more sensitive than wild-type, but significantly less than observed for the single mutant. The large increase m K r for this mutant compared to wild-type suggests that ATP binding is also weaker. However, for other pyridmyl- imidazole compounds tested, the double mutant shows ennanced sensitivity relative to both wild-type and the single mutant enzymes. The results are shown m Table 2, below. TABLE 2. K M for ATP-bmdmg and K for pyridmyl- imidazole inhibition of JNK3 and JNK3 mutants. ENZYME KM FOR ATP (μM) SB202190 Ki (NM) JNK3 (wild-type) 15 1000 JNK3 (M146A) 75 0.23 JNK3 (M146A/D150G) 311 1.5 EXAMPLE 5 Crystallization and Structure Determination of the ERK2 (5X) /SB203580 Complex Crystals of unphosphorylated ERK2(5X) were grown by vapor diffusion when protein (14 mg/ml m 20 mM Tπs, pH 7.0, 5 mM DTT, 200 mM NaCl) was mixed with reservoir (100 mM HEPES, pH 7.2, 28-30% (v/v) PEGMME2000, 200 mM (NH SO , 20 mM β-ME) at a equal volume ratio of protein solution to reservoir and allowed to stand at room temperature. Prior to X-ray data collection at -169°C, a single crystal was equilibrated for 48 h m 100 mM HEPES pH 7.0, 200 mM (NH ) 2 S0 4 , 28% PEGMME2000, 5% -31- glycerol, 2% DMSO, and 1 mM SB203580. X-ray data were collected on an Raxis IIC image plate and processed and scaled using DENZO and SCALEPACK [Z. Otwmowski et al . , Meth. Enzymol., 276, pp. 307-326 (1996)]. The crystals had space group symmetry P21, with unit cell dimensions a=48.6A, b=69.7A, c=60.3A and b=109.25. R-merge for the data was 3.2%, with I/sιg(I)=8.9 at 1.95A resolution. The X-ray data comprised 26,737 unique reflections with |F| > σ(F) derived from 69,783 intensity measurements. The data were 96.7 " complete overall and 83.2% complete in the 2.01-1.95 A resolution shell. X-ray coordinates of unphosphorylated ERK2 were used to construct a model for the refinement of the inhibited ERK2(5X) complex. All thermal factors were set to 20.0 A . The R-factor after the rigid body and positional refinement was 30% for 10-2.4 A data. The resolution of the maps and model was gradually increased to 2.0A resolution by cycles of model building, positional refinement, and thermal factor refinement, interspersed with torsional dynamics runs. XPLOR was used for model refinement [A. T. Brunger, XPLOR: A system for X-ray crystallography & NMR, Ed., Yale University Press, New Haven, CT (Version 3.1) (1992)]. Our current ERK2(5X) model in complex with SB203580 contains 334 protein residues, 283 water molecules, one sulfate molecule, and one inhibitor molecule, and has an R-factor of 21.3 (R-free = 28.6%) versus all data with |F| > σ(F) between 6-2.0 A resolution (23,621 reflections). PROCHECK and XPLOR was used to analyze the model stereochemistry. Ninety percent of the ERK2 residues were located m the most favored region of the -32- phi-psi plot, and 11% m the additional allowed regions. Deviations from ideal bond lengths and angles were 0.009A and 1.5° respectively, and other indications of stereochemistry were average or better then average for a structure determined at 2. OA resolution. No electron density was observed for ERK2(5X) ammo acids 1-13, 31- 33, and 328-335, so these residues were not included m the model. The crystal structure revealed the interactions that lead to potent binding of the pyridmyl-imidazole compound, SB203580, with residues m the ATP site of ERK2(5X). The para-fluorophenyl ring of SB203580 was shielded from solvent and was within favorable van der Waals distance (<4.5A) of the carbon atoms of eight ERK2 side chains; V37, A50, K52, 182, 184, L101, and T105. Comparing this structure with that of wild-type ERK2/ATP, showed that the larger glutamme side chain at position 105 m the wild-type protein would prohibit binding of SB203580 by blocking access to the pocket filled by the para-fluorophenyl ring. Additional contacts were made between the pyπdme ring and V39, A52, 184, L106, M108, and L156, while the 4-substιtuted phenyl ring of SB203580 contacted only L156 and C166. The interactions of the methane- sulfonyl group were more extensive, and this group was nearby to D167, N154, S153, and K151. The lmidazole ring contacted V39, K54, L156 and C166, and appeared to assist ιr binding by positioning the three substituents. Despite the high binding affinity, only one hydrogen bond was made between SB203580 and ERK2(5X). -33- EXAMPLE 6 Identification of the Ammo Acid of Other MAP Kinases to Alter for Binding to Pyridmyl-imidazole Compounds The ammo acid sequence of many other MAP kinases have been published. We have analyzed these sequences by protein alignment means and have determined tne ammo acid residue that aligns with threonme 106 of p38. If this ammo acid is significantly different m character to threonme, then, by changing that ammo acid to one with a small side chain (e.g., alanme or threonme) , a mutant kinase can be created which can theoretically bind to a pyridmyl-imidazole inhibitor of p38. That complex can then be subjected to molecular modeling means which would allow for the design of an inhibitor of the corresponding native MAP kinase according to the methods of this invention. This analysis is shown m the table below: TABLE 3. Other MAP kinases for inhibitor design. MAP KINASE SEQ ID NO KEY AMINO ACID ERK6 24 methionme 109 ERK1 25 glutamme 122 p38-δ 26 methionme 107 JNK3-α2 27 methionme 146 JNK2-αl 28 methionme 108 JNK2-βl 29 methionme 108 JNK2 -β2 30 methionme 108 JNK2 31 methionme 108 JNK1 32 methionme 108 JNKl-α2 33 methionme 108 JNKl -βl 34 methionme 108 JNKl -β2 35 methionme 108 p38-β 36 threonme 106 -34- While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.

Claims: -35- CLAIMS We claim: 1. A method for designing an inhibitor of a second serme/threonme kinase or a second tyrosme kinase comprising the steps of: a. identifying ammo acids m an ATP binding site of a first serme/threonme kinase or a first tyrosme kinase which form close contacts with a compound bound to said ATP binding site; b. employing protein alignment means to identify a second serme/threonme kinase or a second tyrosme kinase that form some, but not all, of the close contacts formed between said compound and said first serme/threonme kinase or said first tyrosme kinase; c. altering an ammo acid m the ATP binding site of said second serme/threonme kinase or said second tyrosme kinase to create a mutant second serme/threonme kinase or a mutant second tyrosme kinase, wherein said compound binds with at least 10-fold greater affinity to said mutant second kinase than to said second kinase; d. confirming that said compound binds with greater affinity to said mutant second serme/threonme kinase or said mutant second tyrosme kinase than to said second serme/threonme kinase or said second tyrosme kinase; and e. using molecular modeling means to modify said compound to create an inhibitor of said second Kinase, such that said inhibitor binds to said second kinase with at least 10-fold greater affinity than said compound binds to said second kinase. ■ 36- 2. The method according to claim 1, wherein said first serme/threonme kinase or tyrosme kinase and said second serme/threonme kinase or tyrosme kinase are both MAP kinases. 3. The method according to claim 2, wherein said first serme/threonme kinase or tyrosme kinase is p38 having the ammo acid sequence set forth m SEQ ID NO: 1. 4. The method according to claim 3, wherein said compound is a pyridmyl-imidazole inhibitor of p38. 5. The method according to claim 4, wherein said compound is selected from SB203580 or SB202190. 6. The method according to claim 2, wherein said second serme/threonme kinase or tyrosme kinase is selected from: a. ERK2 having the ammo acid sequence set forth m SEQ ID NO: 2, wherein ammo acid 103 is lsoleucme, ammo acid 105 is glutamme, ammo acid 106 is aspartic acid, ammo acid 109 is glutamic acid and ammo acid 110 is threonme; or b. JNK3 comprising ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is methionme and ammo acid 150 is aspartic acid. 7. The method according to claim 6, wherein a. when said second kinase is ERK2 , said mutant second kinase is an ERK-2 mutant having an ammo -37- acid sequence as set forth m SEQ ID NO: 2, wherein ammo acid 105 is threonme or alanme; or b. wherein said second kinase is JNK3, said mutant second kmase is a JNK3 mutant comprising ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is alanme or threonme. 8. The method according to claim 7, wherein m SEQ ID NO: 2 ammo acid 103 is leucme, ammo acid 106 is histidme, ammo acid 109 is glycine and ammo acid 110 is alanme. 9. The method according to claim 7, wherein m SEQ ID NO: 3 ammo acid 150 is glycine. 10. A mutant second serme/threonme kinase or tyrosme kinase characterized by: a. at least one ammo acid substitution m an ATP binding site as compared to a corresponding naturally occurring second kmase; b. the ability to bind with a K λ or a K d of less than 10 μM a compound that binds to an ATP binding site of a first serme/threonme kinase or tyrosme kinase; and c. the ability to bind said compound with at least a 10-fold lower K or K d than the K x or K α for said compound with said second kinase. 11. The mutant second kinase according to claim 10, wherein said first and said second kinases are MAP kinases. - 38- 12. The mutant second kinase according to claim 11, wherein said mutant second kinase is selected from: a. a mutant ERK2 consisting of the ammo acid sequence as set forth m SEQ ID NO: 2, wherein ammo acid 105 is threonme or alanme; or b. a mutant JNK3 comprising ammo acids 40-402 of SEQ ID NO: 3, wherein ammo acid 146 is threonme or alanme. 13. The mutant second kinase according to claim 12, wherein m SEQ ID NO:2 ammo acid 103 is leucme, ammo acid 106 is histidme, ammo acid 109 is glycine and ammo acid 110 is alanme. 14. The mutant second kinase according to claim 12, wherein m SEQ ID NO: 3 ammo acid 150 is glycine . 15. A crystallizable co-complex of a mutant second kinase according to any of claims 10 to 14 and an inhibitor of said first kinase bound to the ATP binding site of said mutant second kmase. 16. The crystallizable co-complex according to claim 13, wherein said first kinase is p38, said second kinase is a MAP kinase and said inhibitor is a pyridmyl- imidazole mhioitor of p38. 17. The co-complex according to claim 13, wherein said pyridmyl-imidazole inhibitor of p38 is selected from SB203580 or SB202190.

Inventors: FOX EDWARD, GERMANN URSULA A, SU MICHAEL S, WILSON KEITH P, FOX, EDWARD, GERMANN, URSULA, A., SU, MICHAEL, S., WILSON, KEITH, P.
Applicants: VERTEX PHARMA, VERTEX PHARMACEUTICALS INCORPORATED
Application year: 1999
Main classification: C12N15
IPC codes: C12N9, C12N15, C12Q1